X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4292) 4292
Publication (520) 520
Book Review (93) 93
Book Chapter (14) 14
Conference Proceeding (6) 6
Paper (2) 2
Data Set (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2835) 2835
humans (2468) 2468
oncology (1547) 1547
phase-3 (1465) 1465
male (1211) 1211
phase-3 trial (1204) 1204
female (1186) 1186
double-blind (1072) 1072
open-label (953) 953
middle aged (896) 896
chemotherapy (844) 844
aged (764) 764
adult (704) 704
treatment outcome (667) 667
cancer (621) 621
care and treatment (621) 621
multicenter (542) 542
pharmacology & pharmacy (527) 527
survival (524) 524
efficacy (496) 496
analysis (483) 483
safety (468) 468
therapy (464) 464
patients (462) 462
multiple sclerosis (453) 453
metastasis (416) 416
placebo-controlled phase-3 (403) 403
clinical neurology (396) 396
drug therapy (391) 391
trial (383) 383
clinical trials (380) 380
1st-line treatment (366) 366
controlled phase-3 trial (354) 354
medicine & public health (349) 349
research (349) 349
randomized phase-3 trial (329) 329
hematology (324) 324
immunology (320) 320
aged, 80 and over (318) 318
animals (290) 290
retrospective studies (284) 284
mutation (283) 283
antineoplastic agents - therapeutic use (282) 282
antineoplastic combined chemotherapy protocols - therapeutic use (278) 278
health aspects (277) 277
medicine, general & internal (274) 274
prognosis (273) 273
disease-free survival (255) 255
placebo-controlled trial (253) 253
medical research (233) 233
cancer therapies (217) 217
young adult (217) 217
survival analysis (216) 216
immunotherapy (215) 215
surgery (214) 214
studies (212) 212
radiotherapy (208) 208
urology & nephrology (206) 206
prostate cancer (203) 203
risk factors (203) 203
neurosciences (201) 201
review (200) 200
tumors (200) 200
erlotinib (199) 199
randomized controlled trials as topic (197) 197
infectious diseases (192) 192
gefitinib (188) 188
abridged index medicus (187) 187
adenocarcinoma (187) 187
hematology, oncology and palliative medicine (184) 184
genetic aspects (183) 183
adolescent (178) 178
medicine, research & experimental (177) 177
article (176) 176
quality of life (175) 175
usage (175) 175
disease progression (174) 174
patient outcomes (174) 174
internal medicine (173) 173
lung neoplasms - drug therapy (172) 172
lung cancer (171) 171
respiratory system (170) 170
oral bg-12 (165) 165
medicine, experimental (164) 164
quality-of-life (163) 163
breast cancer (160) 160
development and progression (160) 160
management (160) 160
bevacizumab (158) 158
dimethyl fumarate (157) 157
cell lung-cancer (153) 153
diagnosis (152) 152
multiple sclerosis - drug therapy (148) 148
metastases (145) 145
neoplasm staging (145) 145
randomized phase-3 (145) 145
interferon (143) 143
gastroenterology & hepatology (141) 141
neurology (140) 140
protein kinase inhibitors - therapeutic use (139) 139
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4116) 4116
German (83) 83
French (57) 57
Spanish (25) 25
Hungarian (6) 6
Russian (4) 4
Georgian (1) 1
Japanese (1) 1
Korean (1) 1
Polish (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


NATURE REVIEWS CLINICAL ONCOLOGY, ISSN 1759-4774, 09/2016, Volume 13, Issue 9, pp. 535 - 535
In a recent study, the addition of olaratumab to doxorubicin chemotherapy for patients with soft-tissue sarcoma resulted in prolongation of progression-free... 
ONCOLOGY | CONTROLLED PHASE-3 TRIAL
Journal Article
NEW ENGLAND JOURNAL OF MEDICINE, ISSN 0028-4793, 04/2017, Volume 376, Issue 14, pp. 1390 - 1391
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2018, Volume 36, Issue 22, pp. 2251 - 2258
Purpose The phase III PROFILE 1014 trial compared crizotinib with chemotherapy as first-line treatment in patients with anaplastic lymphoma kinase (ALK)... 
TRIALS | ONCOLOGY | CERITINIB | ADENOCARCINOMA | ALECTINIB | INHIBITORS | PHASE-3 | RETROSPECTIVE ANALYSIS
Journal Article
ONCOLOGY RESEARCH AND TREATMENT, ISSN 2296-5270, 11/2016, Volume 39, Issue 11, pp. 744 - 744
Journal Article
Leukemia Research, ISSN 0145-2126, 01/2019, Volume 76, pp. 96 - 97
Journal Article
CANCER RESEARCH, ISSN 0008-5472, 09/2019, Volume 79, Issue 17, pp. 4326 - 4330
Hepatocellular carcinoma (HCC) has emerged as a major cause of cancer deaths globally. The landscape of systemic therapy has recently changed, with six... 
DOUBLE-BLIND | PHASE-3 | ONCOLOGY | SORAFENIB
Journal Article
EUROPEAN JOURNAL OF DERMATOLOGY, ISSN 1167-1122, 01/2019, Volume 29, Issue 1, pp. 107 - 108
Journal Article
ONCOLOGY RESEARCH AND TREATMENT, ISSN 2296-5270, 10/2017, Volume 40, Issue 10, pp. 635 - 635
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2018, Volume 36, Issue 22, pp. 2244 - 2250
PurposeARCHER 1050, a randomized, open-label, phase III study of dacomitinib versus gefitinib in treatment-naive patients with advanced non-small-cell lung... 
1ST-LINE TREATMENT | CONTROLLED-TRIAL | MULTICENTER | ONCOLOGY | ADENOCARCINOMA | PHASE-3 TRIAL | OPEN-LABEL | AFATINIB | INHIBITOR | CHEMOTHERAPY | ERLOTINIB
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 10/2014, Volume 32, Issue 30, pp. 3459 - 3460
Journal Article
ONCOLOGY RESEARCH AND TREATMENT, ISSN 2296-5270, 2018, Volume 41, Issue 7-8, pp. 492 - 492
Journal Article
The Journal of antimicrobial chemotherapy, ISSN 0305-7453, 06/2019, Volume 74, Issue 6, pp. 1751 - 1753
Journal Article
LANCET ONCOLOGY, ISSN 1470-2045, 04/2012, Volume 13, Issue 4, pp. E142 - E142
Journal Article
LANCET ONCOLOGY, ISSN 1470-2045, 08/2016, Volume 17, Issue 8, pp. E315 - E315
Journal Article
Neurology, ISSN 0028-3878, 04/2019, Volume 92, Issue 15, pp. 696 - 697
Journal Article
ONCOLOGY RESEARCH AND TREATMENT, ISSN 2296-5270, 05/2015, Volume 38, Issue 5, pp. 259 - 259
Journal Article
Journal of Investigative Dermatology, ISSN 0022-202X, 02/2019, Volume 139, Issue 2, pp. 316 - 323
In psoriasis patients, incidence rates of Crohn disease (CD) and ulcerative colitis (UC) have been increased in epidemiological studies and certain clinical... 
MODERATE | REGISTER | SAFETY | IXEKIZUMAB | BRODALUMAB | PHASE-3 | EPIDEMIOLOGY | DERMATOLOGY
Journal Article
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, ISSN 0305-7453, 09/2018, Volume 73, Issue 9, pp. 2480 - 2484
Objectives: To examine the impact of transmitted drug resistance (TDR) on response to first-line regimens with integrase strand transfer inhibitors (INSTIs) or... 
TRIAL | INFECTIOUS DISEASES | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | PHASE-3 | REGIMENS
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.